Cover Image
市場調查報告書

C型肝炎病毒 (HCV) 外膜蛋白E2:開發中產品分析

Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 364864
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
C型肝炎病毒 (HCV) 外膜蛋白E2:開發中產品分析 Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H1 2018
出版日期: 2018年02月20日 內容資訊: 英文 42 Pages
簡介

本報告提供以C型肝炎病毒 (HCV) 外膜蛋白E2為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

C型肝炎病毒 (HCV) 外膜蛋白E2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Integrated BioTherapeutics, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1313TDB

Summary:

Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 13 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H1 2018, outlays comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hepatitis C Virus Envelope Protein E2 - E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral membrane and functions as a host receptor binding protein mediating entry into host cells. It is an important target for the design of entry inhibitors and vaccine immunogens. The molecules developed by companies in Phase II and Preclinical stages are 1 and 5 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 3 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Hepatitis C and Genital Warts (Condylomata Acuminata).

Furthermore, this report also reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2
  • The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatitis C Virus Envelope Protein E2 - Overview
    • Hepatitis C Virus Envelope Protein E2 - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Hepatitis C Virus Envelope Protein E2 - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Hepatitis C Virus Envelope Protein E2 - Companies Involved in Therapeutics Development
    • Aviragen Therapeutics Inc
    • Ennaid Therapeutics LLC
    • Integrated BioTherapeutics Inc
    • Toray Industries Inc
  • Hepatitis C Virus Envelope Protein E2 - Drug Profiles
    • CIGB-230 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis C (strain H77) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis C (virus-like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis C vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hepatitis C vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit E2 for Hepatitis C - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit E1 and E2 Glycoprotein for HCV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teslexivir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatitis C Virus Envelope Protein E2 - Dormant Products
  • Hepatitis C Virus Envelope Protein E2 - Discontinued Products
  • Hepatitis C Virus Envelope Protein E2 - Product Development Milestones
    • Featured News & Press Releases
      • Nov 29, 2017: Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma
      • Feb 08, 2016: Biota Commences Dosing in Phase 2 Trial of Antiviral Therapy BTA074 for Topical Treatment of Condyloma
      • Oct 31, 2013: Results of Anaconda Pharma's Phase IIa study released
      • Jun 10, 2013: IBT and Stanford Awarded STTR
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Aviragen Therapeutics Inc, H1 2018
  • Pipeline by Ennaid Therapeutics LLC, H1 2018
  • Pipeline by Integrated BioTherapeutics Inc, H1 2018
  • Pipeline by Toray Industries Inc, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top